Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy

NCT ID: NCT02056548

Last Updated: 2014-02-06

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 126 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2018-12-31

Brief Summary

Previous studies dealt with patients who maintained antiviral drugs for 2 ~ 6 months after final chemotherapy and they revealed that many of the patients who stopped preemptive antiviral drug within 6 months experienced viral reactivation. Based on the study results, guidelines recommend that preemptive antiviral therapy should be maintained for at least 6 months. Nevertheless, many clinicians apply the preemptive antiviral drugs for 1~2 years or longer after final chemotherapy without definite evidences, and this practice increases the medical expenditure a lot. Therefore, the investigators are going to find out the proper and safe duration of preemptive antiviral therapy which can be a good reference in the future practice.

Detailed Description

HBV reactivation in cancer patients is important not only for directly affecting severe hepatic failure but also for delaying of the further cancer treatments which may cause reduction of overall survival. Thus the guidelines according to the previous studies and other follow-up of randomized studies revealed that patients with positive HbsAg should be administered with preemptive antiviral therapy at least 6 month or more.

However, ideal duration for preemptive antiviral therapy to suppress viral reactivation and withdrawal hepatitis is not clearly identified at present time. It is because previous data just dealt with the efficiency of preemptive antiviral therapy, but most of them did not analyze the outcomes after withdrawal of antiviral therapy. Frequent late-onset reactivation hepatitis in association with preemptive antiviral therapy is mainly due to drug-resistance or post-withdrawal manifestation. Drug-resistance was mainly associated with lamivudine which is now substituted by entecavir or tenofovir which produce lower incidence of resistance (< 1.2% at 6 years). Therefore, the only issue at present is withdrawal hepatitis which may be due to early cessation of the antiviral drug.

Conditions

Lymphoma; Chronic Hepatitis B

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• 18 years old or older
• ECOG performance status 0, 1, 2
• Hodgkin's or Non-Hodgkins lymphomas according to the WHO 2008 classification
• Patients who received standard cytotoxic chemotherapies
• Patients who finished chemotherapy (duration not exceeded 6 months) or who will finish the planned chemotherapy
• Patients who achieved at least partial response and do not need further chemotherapy
• HBsAg (+) patients who received preemptive antiviral therapies

Exclusion Criteria

• Anti-HCV Ab(+), HIV(+), or autoimmune hepatitis
• Complications due to uncompensated liver cirrhosis
• Child pugh score : 10 points or more
• Hepatocellular carcinoma
• Patients who finish the lymphoma treatments with only radiotherapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Seoul St. Mary's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Jae-Ho, Yoon

Clinical fellowship in Catholic BMT Center

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

CHSCTC-R01-HEPATO

Identifier Type: -

Identifier Source: org_study_id